Industry experts to strengthen DIA’s impact around the world

DIA, the premier professional community and knowledge exchange network for global health care product development, announced today its election of four new members to its Board of Directors.

Newly appointed members include:

• Joseph Scheeren, PharmD, Head of Global Regulatory Affairs, Pharma and Consumer Care, Bayer Healthcare
• Jonathan Sheldon, PhD, Global Vice President, Healthcare, Oracle Health Sciences
• Jeffrey S. Payne, CPA, Chief Financial Officer, Picwell Inc.
• Lingshi Tan, PhD, Chairman and Chief Executive Officer, dMed Company Limited

“With shifts in the environment toward targeted, personalized treatments to improve patient care, it is apparent that the old paradigm of drug development is no longer sustainable,” said Barbara Lopez Kunz, Global Chief Executive, DIA. “There is still much to be done to advance the personalized model of care and, with the addition of these industry experts, our leadership team will continue to strengthen DIA’s ability to take innovation to scale and increase our impact around the world.”

As part of their responsibilities, the new board members will help the DIA to:

• Define the future innovative offerings delivered through DIA’s knowledge platform for new stakeholder value.
• Sustain and enhance DIA’s globalization model for engagement/ and escalation with appropriate financial and non-financial milestones.
• Re-imagine the DIA governance model and the transition plan for the future.
• Support DIA’s vision via strategic relationships with visionary, like-minded organizations to multiply DIA’s impact on health.

“We are pleased to welcome the new members to the DIA Board of Directors and look forward to their expertise to continue advancing innovation worldwide; underscoring DIA’s vital role in generating new knowledge across the globe,” Kunz said.